Our NexVas™ Plaque Regression program has the world lead in developing ApoA‑I production small molecules that enhance Reverse Cholesterol Transport with our First‑in‑Class drug RVX‑208.
RVX-208, the first drug of its kind enters landmark Phase 2b IVUS Clinical Trial ASSURE led by Cleveland Clinic.
Expanding technology franchise, NexVas™ Alzheimer's Disease and our Autoimmune Drug Development Program for multiple indications.
2011 Annual Report
NexVas™ Animation
